Given the lethality of GBM and the limited effectiveness of current treatment modalities, advancements such as the application of minimal TIMP variants could bring novel therapeutic approaches, offering new avenues for controlling tumor spread to improve the survival and quality of life for patients battling this formidable brain tumor. The gene discussed is TIMP1; the disease is neoplasm.